A Phase 3 interventional study of Botulinum toxin type A and Strabismus surgery in Acquired Esotropia, sponsored by Insel Gruppe AG, University Hospital Bern. Completed at 8 sites in 2 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2023-11-07.
Sponsored by Insel Gruppe AG, University Hospital Bern · Phase 3, Interventional, and Treatment
The purpose of the study is to evaluate if strabismus can be successfully treated requiring less surgical interventions with a Botox-based treatment regimen compared to a purely surgery based treatment regimen.
Experimental arm: Botulinum toxin injection in the horizontal extraocular muscles.
Control (active comparator) arm: Strabismus surgery on the horizontal extraocular muscles. No investigational product is used.
In Switzerland the standard procedure for treating large angle esotropia is surgery, which is performed on the horizontal eye muscles that may be either recessed or shortened leading to reduced or increased muscle function respectively.
As an alternative to strabismus surgery, botulinum toxin (Botox) can be applied in extraocular muscles. Botox prevents the release of acetylcholine in the synaptic cleft and thereby blocks the neuromuscular transmission thus inducing a palsy.
Current evidence on the use of Botox in strabismus is incoherent, is poorly supported by basic research findings and leaves dedicated clinicians in the dark. The objective is to shed light into this field of clinical research, which may help to guide future pediatric ophthalmologists in their management of strabismic patients. In a best case scenario, the results from this trial will prevent strabismus operation for many children with acquired large angle esotropia.
Patients with acquired large angle esotropia (an inward deviation of the ocular axis by more than 5°) that develops after one year of age have a potential to regain binocular vision if a retinal image appears on corresponding retinal areas of both eyes. The main goal of therapy in these patients is the restoration of binocular vision.
In Switzerland the standard procedure for treating large angle esotropia is surgery, which is performed on the horizontal eye muscles that may be either recessed or shortened leading to reduced or increased muscle function respectively.
As an alternative to strabismus surgery, botulinum toxin (Botox) can be applied in extraocular muscles. Botox prevents the release of acetylcholine in the synaptic cleft and thereby blocks the neuromuscular transmission thus inducing a palsy.
Current evidence on the use of Botox in strabismus is incoherent, is poorly supported by basic research findings and leaves dedicated clinicians in the dark. The goal is to shed light into this field of clinical research, which may help to guide future pediatric ophthalmologists in their management of strabismic patients.
The goal of the study is to test if, with a botulinum-toxin-based treatment regimen, strabismus can be successfully treated requiring less surgical interventions.
The primary objective is to test if the Botox-based treatment regimen is not inferior to surgical treatment in terms of orthotropic success. If this is shown, the number of surgeries required will be compared between the two groups (main secondary objective).
The hypothesis is that the Botox-based treatment regimen, which permits performance of rescue surgery, is successful in a similar proportion of patients as the purely surgical approach. The second hypothesis is that only about 20% of patients treated with Botox require surgery at all as compared to about 10% of patients in the surgical arm that need a second surgery.
Analysis of the primary outcome The proportion of orthotropic success for both groups will be calculated with a corresponding 95% confidence interval. For the comparison between the two groups, the stratified risk difference for the stratification factors used in randomization will be calculated with a corresponding one-sided lower 95% confidence limit. If the lower limit lies above -12%, non-inferiority will be claimed.
Analysis of the main secondary outcome The proportion of second interventions for both groups will be calculated with a corresponding 95% confidence interval. For the comparison between the two groups, a stratified risk difference for the stratification factors used in randomization will be calculated with a corresponding one-sided upper 95% confidence limit. If the upper limit lies below 40% and if non-inferiority for the primary outcome could be demonstrated, a clinical benefit of the new treatment will be claimed.
Any of the following:
Positive test of binocular function at any time point in the past, including any of the following
Exclusion Criteria:
Any of the following:
Presence of ophthalmic pathologies significantly preventing binocular functions.
A significant alteration of binocular function is assumed if vision is smaller than 0.1 or the visual field has a horizontal diameter of less than 20°.
First intervention is a Botulinum toxin type A injection. If further treatment is necessary, strabismus surgery can be performed.
Drug: Botulinum toxin type A · Procedure: Strabismus surgery
First intervention is strabismus surgery. If further treatment is necessary, strabismus surgery can be repeated.
Procedure: Strabismus surgery
Botulinum toxin injection in the horizontal extraocular muscles.
Strabismus surgery on the horizontal extraocular muscles
Number of patients with presence of binocular vision
Presence of binocular vision is a binary variable set to yes when either of the following criteria is fulfilled: 1. No eye movement can be observed in the simultaneous prism covertest, performed according to the study specific SOP for full orthoptic workup, for both eyes measured at distance. This proves orthotropia and thus binocular vision can be assumed. 2. An esotropia of less than 5° is observed in the covertest at distance AND at near. In addition at least one binocular test demonstrates binocular vision. This proves compensated microstrabismus with anomalous retinal correspondence. Binocular tests: 1. Lang-Stereotest 2. Butterfly- Stereotest 3. Titmus test 4. Bagolini striated glasses test 5. TNO-Test 6. Pencil-Test
Time frame: At 18 months
Number of patients with second intervention
Rescue surgery in Botox-based treatment arm and second surgery in surgery arm
Time frame: At 12 months, at 18 months
Number of patients with binocular vision
Presence of binocular vision is a binary variable set to yes when either of the following criteria is fulfilled: 1. No eye movement can be observed in the simultaneous prism covertest, performed according to the study specific SOP for full orthoptic workup, for both eyes measured at distance. This proves orthotropia and thus binocular vision can be assumed. 2. An esotropia of less than 5° is observed in the covertest at distance AND at near. In addition at least one binocular test demonstrates binocular vision. This proves compensated microstrabismus with anomalous retinal correspondence. Binocular tests: 1. Lang-Stereotest 2. Butterfly- Stereotest 3. Titmus test 4. Bagolini striated glasses test 5. TNO-Test 6. Pencil-Test
Time frame: At 12 months
Number of patients with incomitance
Incomitance is here defined as the absolute difference of strabismus angle measured with the alternate prism cover test at 25° left gaze and the angle measured at 25° right gaze
Time frame: At 12 months, at 18 months
Number of patients with treatment-specific presence of binocular vision
For this outcome patients with a second intervention are defined as failures (no).
Time frame: At 12 months, at 18 months
Number of surgeries per participant
Time frame: At 12 months, at 18 months
Number of surgeries needed per successful outcome
Successful outcome = binocular vision
Time frame: At 12 months, at 18 months
Change in strabismus angle, measured in percent
Measured as percentage of preoperative deviation from baseline. The strabismus angle measured with the alternate prism cover test, performed in primary position at distance is used. Change of deviation in percent of preoperative deviation is calculated as follows: 100\*(preoperative deviation - postoperative deviation) / preoperative deviation
Time frame: At 12 months, at 18 months
Binocular function, measured in arc seconds
When binocular vision is present, the binocular function is the best stereoscopic acuity, measured in arc seconds, achieved for any of the below mentioned tests. 1. Lang-Stereotest 2. Butterfly- Stereotest 3. Titmus test 4. Bagolini striated glasses test 5. TNO-Test 6. Pencil-Test
Time frame: At 12 months, at 18 months
Total duration of binocular vision (exploratory outcome)
The duration is calculated as the sum of time periods between consecutive assessments with presence of binocular vision.
Time frame: At 12 months, at 18 months
Incidence of short-term adverse events (safety outcome)
Adverse event groups that will be evaluated separately are: * Ptosis * Double vision * Subjective post-treatment discomfort/pain * New vertical strabismus \>1° * Limitations of ocular motility
Time frame: Within two weeks of intervention
Incidence of ocular adverse events
Time frame: Within 18 months
Incidence of serious adverse events related to the treatment
Time frame: Within 18 months
Plan to share: Yes — The de-identified study dataset will be made publicly available for secondary analyses by publishing the data on a data sharing platform such as Dryad or BORIS, the public online data repository from the University of Bern.
Supporting information: Study protocol, Sap
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern